Ocuphire Pharma, Inc. (OCUP)

Ocuphire Pharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	-11.3	-9.99	17.89	-56.69	-24.62	-6.17
Depreciation & Amortization	0.01	0.01	0	0	0.01	0
Share-Based Compensation	3.69	3.51	1.81	1.91	1.51	0.31
Other Operating Activities	4.42	5.36	-5.39	35.41	16.31	2.27
Operating Cash Flow	-3.18	-1.11	14.31	-19.37	-6.8	-3.59
Capital Expenditures	0	0	0	0	0	-0.03
Acquisitions	0	0	0	-0.1	0.54	0
Investing Cash Flow	0	0	0	-0.1	0.54	-0.03
Share Issuance / Repurchase	11.42	8.98	4.32	27.07	0.06	0
Debt Issued / Paid	0	0	-0.54	0.54	23.35	4.7
Other Financing Activities	-0.06	-	-	-	-2.29	-
Financing Cash Flow	11.36	8.98	3.79	27.61	21.12	4.7
Net Cash Flow	8.17	7.87	18.1	8.14	14.86	1.09
Free Cash Flow	-3.18	-1.11	14.31	-19.37	-6.8	-3.62
Free Cash Flow Margin	-16.74%	-5.84%	35.92%	-3288.62%	-	-
Free Cash Flow Per Share	-0.13	-0.05	0.72	-1.30	-1.46	-1.27

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).